Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
CONCLUSION: Effective reduction of blood pressure to accepted goals is the key to reduce the risk of CV events and stroke. Dual inhibition of neprilysin and the angiotensin receptor with sacubitril/valsartan may represent an attractive and serendipitous therapeutic approach for a range of CV diseases, including hypertension and HF, in which vasoconstriction, volume overload and neuro-hormonal activation play a part in pathophysiology. Sacubitril/Valsartan appears to be more efficacious in reducing blood pressure than currently available ACEi and ARBs with a similar safety and tolerability profile. Besides, pleiotropic benefits like HbA1c reduction, better eGFR progression and a greater decrease in blood pressure and serum creatinine levels make this drug a novel addition to the current hypertension armamentarium.
PMID: 30122239 [PubMed - in process]
Source: Indian Heart J - Category: Cardiology Authors: Dargad RR, Prajapati MR, Dargad RR, Parekh JD Tags: Indian Heart J Source Type: research
More News: Brain | Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Diovan | Emergency Medicine | Health Management | Heart | Heart Failure | Hormones | Hypertension | India Health | Neurology | Statistics | Stroke | Study | Websites